Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer
NCT01003808
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
25
Enrollment
INDUSTRY
Sponsor class
Conditions
Esophageal Cancer
Interventions
BIOLOGICAL:
IMF-001
Sponsor
ImmunoFrontier, Inc.